blue cross blue shield glp-1 coverage 2025 Pharmacy Benefits With BCBSTX BCBSM pulling back on GLP-1
Description
Thus, it can be designed as a self-boosting system therefore it can release therapeutics in a repeated, controlled, and programmed manner
In trials for MASH, survodutide demonstrated significant reduction in liver fat and improvement in liver fibrosis scores
The outcomes of these studies mainly concern weight loss and the improvement of anthropometric parameters
Some plans may cover these treatments when prescribed for a qualifying diagnosis such as obesity (BMI 30) or overweight (BMI 27) with a weight-related comorbidity
